Pharmaceutical composition for preventing or treating DYRK-related diseases, containing pyridine-based compound as active ingredient

A method for treating or improving DYRK-related diseases in a subject in need thereof comprising:

• a compound or a pharmaceutically acceptable salt thereof represented by formula 1 below as an active ingredient:
• (in formula 1 above,
• R1 is a hydrogen or —NR6R7, wherein R6 and R7 are each independently a hydrogen, a C1-C5 straight or branched chain alkyl or benzyl;
• R2, R3 and R4 are each independently a hydrogen, a halogen, a C1-C5 straight or branched chain alkyl, —NR8R9, OR8, —CN, —NHC(O)R8, —SO2R8, —OS(O)2R8, pyrrolidine, piperidine, or morpholin, wherein R8 and R9 are each independently a hydrogen, a C1-C5 straight or branched chain alkyl, a C1-C5 straight or branched chain alkynyl, a C6-C12 straight or branched chain alkenyl, a C6-C12 aryl, a C6-C12 aryl substituted with a halogen, or a C6-C12 aryl substituted with a trihalogen methyl;
• and
• R5 is a hydrogen, a C1-C5 straight or branched chain alkyl, unsubstituted 4-piperidine, acetyl-substituted 4-piperidin;
• wherein the DYRK-related disease is at least one disease selected from the group consisting of Down syndrome, degenerative brain diseases and metabolic diseases.